Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
IPO flop: Tissue Repair (ASX:TRP) share price plunges 40% since listing
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.
|05 Dec 2023||$0.24||$0.01||4.26%||3,600||$0.24||$0.24||$0.24|
|04 Dec 2023||$0.24||$0.00||0.00%||14,944||$0.24||$0.24||$0.24|
|01 Dec 2023||$0.24||$-0.01||-4.17%||50,000||$0.24||$0.24||$0.24|
|29 Nov 2023||$0.24||$0.01||4.35%||21,740||$0.24||$0.24||$0.24|
|28 Nov 2023||$0.23||$-0.02||-8.16%||11,688||$0.25||$0.25||$0.23|
|24 Nov 2023||$0.25||$0.01||4.26%||48,955||$0.23||$0.25||$0.23|
|23 Nov 2023||$0.24||$-0.01||-4.17%||24,521||$0.24||$0.24||$0.24|
|22 Nov 2023||$0.24||$-0.01||-4.00%||31,295||$0.24||$0.24||$0.23|
|17 Nov 2023||$0.25||$0.00||0.00%||7,000||$0.23||$0.25||$0.23|
|15 Nov 2023||$0.25||$0.00||0.00%||810||$0.25||$0.25||$0.25|
|14 Nov 2023||$0.25||$0.01||4.08%||83||$0.25||$0.25||$0.25|
|13 Nov 2023||$0.25||$0.00||0.00%||5,414||$0.25||$0.25||$0.25|
|07 Nov 2023||$0.25||$0.00||0.00%||5,714||$0.25||$0.25||$0.25|
|13 Nov 2023||Michael Silberberg||Issued||392,753||$96,224||
Issue of options.
|02 Jun 2023||Jack Lowenstein||Buy||40,000||$11,200||
|30 May 2023||Jack Lowenstein||Buy||35,000||$9,800||
On-market trade. As per announcement on 06-06-2023
|Mr Jack Theseus Lowenstein||Non-Executive ChairmanNon-Executive Director||Aug 2021||
Mr Lowenstein has over 25 years of senior management experience in financial services and was a pioneer in developing Australian ESG investment, first at Hunter Hall Investment Management from 1997 to 2011, and then from 2012 to 2019 at Morphic Asset Management. Both companies specialised in investing in ethically screened global mid-cap equities. Morphic was acquired in 2019 by Ellerston Capital. He was also a co-founder of Fiji's first investment bank, Kontiki Capital which he chaired from its inception in 1998 to 2017, and remains a director of Kinetic Growth Fund, which is listed on the South Pacific Stock Exchange.
|Mr Bryan William Gray||Non-Executive Director||Oct 2021||
Mr Gray has over 35 years' experience in Banking and Financial services in Australia and New Zealand. He spent 20 years at J.P Morgan in the Corporate and Investment Bank, the last 12 years as a Managing Director. Prior to that he held senior roles at State Street Bank . He is currently a non-executive director of RFBI a not-for-profit business operating in the Residential Aged Care and Retirement sector.
|Mr Tony Charara||Co-FounderExecutive Director||May 2012||
Mr Charara is a co-founder of Tissue Repair. He has been involved in the Company's clinical development program, across its two-phase 2B trials, commercialisation strategy and overall operations. Tony is an investment banker by background and has experience across early-stage venture assets and in advising technology companies at ANZ Investment Bank, Ord Minnett Securities and JPMorgan in their investment banking teams. Tony is also a co-founder of Mable Technologies, an online marketplace and health technology platform operating in the aged care and disability sectors. Mable was named Australian growth technology company of the year in 2020. It was also listed in the Top 10 Deloitte Technology Fast 50 in 2020 and 2021. As Tony is a co-founder and has been a Director of Tissue Repair since the Company's incorporation, he is considered by the Board not to be an independent director.
|Dr Michael Silberberg||Non-Executive Director||Apr 2023||
Mr Silberberg is currently the Global Therapeutic Area Head, Facial Aesthetics for AbbVie, based in England. Prior to that he spent nine years working for Allergan in a variety of senior roles, culminating as Executive Medical Director, Aesthetics, International and Global Plastic Surgery Therapeutic Area Lead after starting as Director, Medical Affairs, Australia/NZ.
|Ms Priyamvada Sanjay Rasal (Pia)||Company Secretary||Jun 2023||
|Priyamvada Sanjay Rasal (Pia)||Company Secretary||
|Selene Holdings Ltd||5,955,980||9.85%|
|Spark Capital Pty Limited||4,822,260||7.98%|
|Creight Investments Pty Ltd <987 Trust A/C>||3,031,720||5.01%|
|Welas Pty Ltd <Wales Family Trust A/C>||2,317,580||3.83%|
|Hishenk Pty Ltd||1,700,000||2.81%|
|Bannaby Investments Pty Limited||1,690,580||2.80%|
|Moore Family Nominee Pty Limited||1,217,400||2.01%|
|Super Secret Pty Limited <Tkocz Sf A/C>||1,213,317||2.01%|
|Gidley-Baird Holdings Pty Ltd||1,055,440||1.75%|
|Mr Guy Banducci & Mrs Lisa Maree Banducci <Kali Super Fund A/C>||1,050,000||1.74%|
|Creight Investments Pty Ltd <Scutt Retirement Fund A/C>||990,540||1.64%|
|Warwick Nettle Pty Limited <Warwick Nettle Superannuationfund A/C>||967,040||1.60%|
|Phytose Corporatn Limited <Boundaryone S/F A/C>||793,940||1.31%|
|Terrence Joseph Caplice||730,440||1.21%|
|Dc Scutt Pty Ltd <Dcs Pension A/C>||642,095||1.06%|
|Cinderella Management Company Pty Ltd <The Cinderella Unit A/C>||608,694||1.01%|
|Rg Roden Pty Limited||608,680||1.01%|
|Bmy Group Pty Ltd||543,478||0.90%|
|Scintilla Strategic Investments Limited||512,200||0.85%|